Fragment-based screening (FBS) has become an established approach for hit identification. Starting points identified by FBS, are small fragments that require substantial modification in order to become leads. As fragments are different from classical hits a process tailored for fragment evolution is required. Scores for ligand efficiency have been proposed as guides for this process. Here we review how these have been applied to guide the selection and optimization of fragment hits.
Introduction
A common approach for hit identification is high throughput screening (HTS). 1 In HTS a large number of compounds (~ 10 6 ) is screened to assess biological activity against a target. Nevertheless, considering the theoretically large chemical space of drug-like compounds, 2 the probability of finding hits is relatively low. 3 This has led to the development of alternative approaches such as FBS and fragment-based drug discovery (FBDD). [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Advantages of FBS are a) a more efficient sampling due to the smaller chemical space of fragment-sized compounds 16, 17 and b) a higher probability of fragments possessing good complementarity with the target 18 . Both aspects are likely to be the cause for the higher hit rates which are typically observed for FBS in comparison to HTS. 10 However fragment hits have lower affinities towards the target. As a consequence, more effort has to be spent on optimization to obtain lead compounds with an acceptable affinity. Strategies have been proposed to guide and evaluate this process.
These strategies aim at the efficient optimization of fragments whilst maintaining their generally good physicochemical properties. In this review we discuss various efficiency indices and how to best leverage them in FBDD projects.
Considerations during hit selection and optimization
Traditionally, affinity is the first aspect considered for hit selection and optimization.
However, affinity alone can be misleading as it is often found to be linked with molecular size. Thus a focus on affinity leads to a bias towards a selection of bigger compounds. In addition, optimization of affinity during subsequent stages of drug discovery typically leads to a further increase in molecular weight (MW). 19 Moreover, affinity is often optimized through the introduction of lipophilic groups, as these contribute favourably to the hydrophobic effect without the need for specific interactions with the target. This contrasts with polar groups, which need to establish very good interactions with the target in order to compensate the desolvation penalty. For this reason, polar groups are often used to improve solubility rather than affinity. 20 This phenomenon is reflected in the general trend towards generation of not only bigger but also more lipophilic compounds during the hit optimization process. 19 Ultimately, affinity for the target is not the only aspect that has to be considered during drug discovery. To enter later stages of drug development, a compound needs to have suitable physicochemical properties. Lipinski et al. 21 studied the properties of oral drugs that managed to enter clinical Phase II. The study resulted in the 'Rule-of-Five' stating that poor absorption or permeation are more likely if more than one of the relevant parameters (see Table 1 ) are outside the range typically observed for drug-like compounds.
The 'Rule-of-Five' has had a strong influence on the drug discovery process. Good physicochemical properties help to reduce the attrition rate at later stages towards to market. 22 A recent study showed that almost all ADMET parameters deteriorate with either increasing MW and/or logP. 23 These studies emphasize the importance for selecting appropriate hits and monitoring MW and lipophilicity in addition to affinity during hit optimization
Ligand efficiency scores: Ligand efficiency
In order to escape the affinity-biased selection and optimization towards larger ligands the focus should be directed towards the generation of compounds that use their atoms most efficiently. To estimate the efficiency of compounds, Hopkins et al. 24 group efficiency, compared to the LE of the initial molecule A, will allow to maintain (or increase) the LE during compound optimization.
Fit quality
Reynolds et al. systematically investigated the size-dependence of LE. 27 In this study the binding affinity data and corresponding LEs taken from the BindingDB 28 were plotted against the number on non-hydrogen atoms. Altogether, over 8000 ligands for 28 targets were considered. The result of this study is that the maximum observed ligand efficiency 
Ligand-lipophilicity efficiency
Ligand efficiency and corresponding FQ are useful for optimizing affinity with respect to molecular size. However, to achieve optimal ADMET properties molecular size as well as lipophilicity are important factors to consider. If lipophilicity is too high, the likelihood of a compound to bind to multiple targets increases. 32 In order to facilitate optimization of affinity with respect to lipophilicity, Leeson and Springthorpe 32 defined the ligandlipophilicity efficiency (LLE):
High LLE favours compounds that gain a lot of their affinity through directed interactions thus making the interaction with the receptor more specific.
While one can say that LLE describes how efficient a ligand exploits its lipophilicity, no explicit measure of molecular size is used. Therefore, a lipophilicity corrected LE is needed to enable optimization of affinity without the extensive use of lipophilic nonspecific interactions. Keserü and Makara 19 proposed LELP = logP/LE as monitoring function to achieve that goal, but also other ways to combine molecular size and lipophilicity into a single efficiency measurement are being discussed.
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Application of ligand efficiency scores to FBDD
Clinical candidates are generally preferred to be 'Rule-of-Five' compliant with a special focus on lipophilicity. To achieve this, the starting restrictions for fragments should be obviously stronger. Congreve et al. 34 studied fragment hits that could be successfully optimized into potent leads, and noticed they have particular physicochemical properties.
These properties and congruent thresholds are summarized as the 'Rule-of-Three' (see Table 1 ). To stay within these thresholds has been suggested as a criteria for fragment library design. Table S1 ).
For fragment hit selection, ligand efficiency has become a widely accepted metric. In general, it is best to start with a fragment that shows a high LE since in most cases LE decreases during optimization. Looking at the examples in literature [5] [6] [7] [8] 14 and following the This is illustrated in the example a) in Figure 1 : The LE score of the initial fragment hit is quite high (0.59). Although, LE decreases during fragment growth, the final potent compound (IC50= 3 nM) reaches a LE score of 0.42. This is still a high value which is significantly above the suggested value of about 0.3. Another possible scenario is illustrated by example b): The LE score can be maintained throughout the optimization process. This is achieved through the introduction of groups that have GEs comparable to LE of the starting compound. As long as the initial fragment hit has a LE score > 0.3, also this strategy can lead to potent drug-like compounds. Example c) shows one of the rare cases where LE is increased during fragment growth. Although the LE of the starting fragment is below 0.3, it was possible to significantly improve the affinity by introducing an additional group to finally reach a potent drug-like compound.
Revisiting example a) illustrates the usefulness of FQ (in addition to LE) for fragment optimization. Although LE is decreasing, FQ is maintained, indicating that fragment optimization is on the right track. In general, the goal should be to either maintain or increase FQ during fragment assembly in order to reach a near optimal affinity for the final compound. LLE provides a way to evaluate the affinity of a compound with respect to its lipophilicity. The challenge is to increase potency without increasing lipophilicity at the same time. As lipophilicity is the major factor for promiscuity of compounds, LLE optimized compounds should be more selective. It is suggested to target a LLE in a range of 5-7 or even higher. 32 In example a) LLE is increased during optimization. The final compound reaches a LLE of 7.3 which is even above the suggested range of 5-7. In combination with the acceptable LE of 0.42 this indicates that this compound was successfully optimized. Comparing the cLogP values of the compounds reveals that lipophilicity was kept fairly constant during fragment growth. This means that affinity is mainly gained by introduction of groups making specific directed interactions. In the other two examples, b) and c) LLE is increasing during optimization but none of the compounds reaches a LLE above 5. In these cases the gain of affinity is accompanied by an increase of lipophilicity. In this respect, optimization was not as optimal as in the first example. 
Conclusion
FBDD, as illustrated in Table 1 , typically starts with a 'Rule-of-Three'-compliant fragment and ideally ends up with a potent 'Rule-of-Five'-compliant candidate compound.
Colleagues from Astex proposed that an efficient fragment growth is one where ligand efficiency can be maintained. 4 This goal is further supported by a study which concluded that a linear increase of binding affinity with molecular mass is possible. 39 If maintenance of LE at an acceptable level (LE ≥ 0.3) can be achieved, FQ scores will rise during fragment growth and the affinity of the final compound will approach a near optimal affinity.
At the same time, retrospective studies show that in most cases LE scores decrease during fragment assembly. 5, 7 Still, an acceptable affinity of the final compound can be reached if FQ can be maintained at a high level (FQ ≥ 0.8). Therefore, Bembenek et al. 40 suggested that, unlike ligand efficiency alone, the fit quality score can be used as a measure of efficiency across the entire optimization process from initial fragment hit to optimized clinical candidate.
Another mentionable guide to maintain the good physicochemical properties of fragment hits is to consider LLE during FBDD. Lipinski states in the 'Rule-of-Five' that the cLogP, which is used to calculate the LLE, should be smaller than 5. However, a 10nM
compound with an acceptable cLogP of 5 will have a LLE of 3. This is much smaller than the suggested range of 5-7. 32 In order to achieve a LLE in this range, the cLogP must be smaller than 3. This is in agreement with a recent study which showed that there is an increased risk of adverse outcome with cLogP > 3.
41 Table 2 summarizes the ligand efficiency scores that should be considered during FBDD.
Both, LE and FQ, have been shown to be very helpful in guiding the selection and optimization of fragment hits. In addition, LLE is expected to become increasingly popular to ensure an increase of affinity more than lipophilicity. 
